Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens

[1]  田原 康玄,et al.  生活習慣病とgenome-wide association study , 2015 .

[2]  A. Muir.  IL28B in the era of direct-acting antivirals for hepatitis C. , 2013, Journal of clinical gastroenterology.

[3]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[4]  C. Molony,et al.  Factors that predict response of patients with hepatitis C virus infection to boceprevir. , 2012, Gastroenterology.

[5]  R. Lempicki,et al.  Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B‐unfavorable genotype patients: Impaired viral kinetics and therapeutic response , 2012, Hepatology.

[6]  Stuart K. Roberts,et al.  Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. , 2012, Gastroenterology.

[7]  U. Neumann,et al.  Role of IL28B Polymorphism in the Development of Hepatitis C Virus-Induced Hepatocellular Carcinoma, Graft Fibrosis, and Posttransplant Antiviral Therapy , 2012, Transplantation.

[8]  K. Chayama,et al.  Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus , 2012, Journal of Gastroenterology.

[9]  K. Shianna,et al.  Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. , 2012, Journal of hepatology.

[10]  Xinyue Chen,et al.  Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma , 2012, Cancer Immunology, Immunotherapy.

[11]  A. Rauch,et al.  Genetic Variations in IL28B and Allergic Disease in Children , 2012, PloS one.

[12]  X. Lao,et al.  Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. , 2011, Journal of hepatology.

[13]  A. Neumann,et al.  IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. , 2011, Journal of hepatology.

[14]  F. Lammert,et al.  Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rsI2979860 polymorphism of the IL28B gene , 2011, European journal of medical research.

[15]  G. Alexander,et al.  A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection , 2011, Gastroenterology.

[16]  Staffan Nilsson,et al.  Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. , 2011, The Journal of infectious diseases.

[17]  M. Pirisi,et al.  Role of Interleukin 28B rs12979860 C/T Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship with Gender and Viral Genotype , 2011, Journal of Clinical Immunology.

[18]  J. Salmerón,et al.  Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV‐infected children , 2011, Hepatology.

[19]  M. Pirisi,et al.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. , 2011, Journal of hepatology.

[20]  H. Nomura,et al.  The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B , 2011, Journal of Clinical Microbiology.

[21]  Julia E. Vogt,et al.  Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. , 2011, Gastroenterology.

[22]  K. Shianna,et al.  IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C , 2010, Hepatology.

[23]  K. Shianna,et al.  A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. , 2010, Gastroenterology.

[24]  Yusuke Nakamura,et al.  Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. , 2010, Journal of hepatology.

[25]  K. Shianna,et al.  An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. , 2010, Gastroenterology.

[26]  K. Horimoto,et al.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. , 2010, Gastroenterology.

[27]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[28]  M. Romero-Gómez,et al.  Interleukin‐28B genetic variants and hepatitis virus infection by different viral genotypes , 2010, Hepatology.

[29]  X. Lao,et al.  Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. , 2010, Gastroenterology.

[30]  J. Beckmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[31]  S. Satapathy,et al.  Equally Poor Outcomes to Pegylated Interferon-based Therapy in African Americans and Hispanics With Chronic Hepatitis C Infection , 2010, Journal of clinical gastroenterology.

[32]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[33]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[34]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[35]  B. Kronenberger,et al.  Current and future treatment options for HCV. , 2009, Annals of hepatology.

[36]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[37]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[38]  P. Killenberg,et al.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.

[39]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[40]  E. Kelly,et al.  an update on , 2014 .

[41]  P. Neuhaus,et al.  Transforming Growth Factor- (cid:1) 1-Gene Polymorphism in the Development of Kidney Disease After Liver Transplantation , 2022 .